Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.

Ko

Kotak Healthcare Fund - Direct Plan - Growth Option

Kotak Mahindra Mutual Fund · Equity · Sectoral/ Thematic

₹18.07

+0.02 (+0.09%)

AUM: —

NAV updated 13 days ago

Plan

Direct

Option

Growth

Risk

Very High

Sharpe Ratio

1.63

Std Dev (1Y)

14.61%

Historical Returns (CAGR)

Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.

1m

+2.5%

3m

+4.31%

6m

+18.97%

1y

+28.3%

3y

—

5y

—

10y

—

since inception

+22.59%

TopFund's Take on Kotak Healthcare Fund - Direct Plan - Growth Option

Kotak Healthcare Fund - Direct Plan - Growth Option is a Sectoral/ Thematic fund from Kotak Mahindra Mutual Fund.

Cost: Expense ratio data for this fund isn't available yet.

Risk-adjusted performance: Over the trailing 1-year period, the fund shows a strong Sharpe ratio of 1.63 — the fund has generated solid returns relative to the volatility it exposed investors to. Separately, annualised volatility of 14.61% is fairly typical for Sectoral/ Thematic funds.

Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.

This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.

Sector Allocation

Sector allocation not available yet.

Asset Allocation

Asset allocation not available yet.

Frequently Asked Questions about Kotak Healthcare Fund - Direct Plan - Growth Option

* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

No comments yet — start the discussion.